FDA Approves Ongentys as Levodopa Add-on for ‘Off’ Periods

FDA Approves Ongentys as Levodopa Add-on for ‘Off’ Periods
The U.S. Food and Drug Administration (FDA) has approved Ongentys (opicapone) as an oral, add-on daily treatment for Parkinson’s disease patients experiencing off periods while on a levodopa/carbidopa regimen. The approval is for 25 mg and 50 mg capsules, either taken once a day. It comes after Ongentys significantly reduced off periods — when the effects of a medication wear off before ... read more
Source: Parkinson’s News TodayPublished on 2020-04-27By Ines Martins, PhD